1.35%| Prev Close: | 0.22 |
|---|---|
| Open: | 0.21 |
| Bid: | N/A |
| Ask: | N/A |
| 1y Target Est: | N/A |
| Beta: | 0.511 |
| Next Earnings Date: | N/A |
| Day's Range: | 0.21 - 0.22 |
|---|---|
| 52wk Range: | 0.15 - 0.79 |
| Volume: | 13,533 |
| Avg Vol (3m): | 26,402 |
| Market Cap: | 12.36M |
| P/E (ttm): | N/A |
| EPS (ttm): | -0.04 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Sunshine Biopharma's Anticancer Drug Candidate, Adva-27a, Is Unaffected by the Recent Supreme Court Ruling on Patentability of Human GenesMarketwired(Wed 8:00AM EDT)
- Sunshine Biopharma Announces That Its Breast Cancer Drug Candidate, Adva-27a, Also Destroys Pancreatic Cancer CellsMarketwired(Tue, Jun 4)
- SUNSHINE BIOPHARMA, INC FinancialsEDGAR Online Financials(Wed, May 15)
- SUNSHINE BIOPHARMA, INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- Sunshine Biopharma Narrows Kilogram Manufacturing Options for Adva-27a Breast Cancer Drug Candidate to Three SuppliersMarketwired(Wed, May 1)
- Sunshine Biopharma HMEC Study Indicates Novel Anticancer Compound Adva-27a Non-Toxic at High ConcentrationsMarketwired(Tue, Apr 9)
- SUNSHINE BIOPHARMA, INC Files SEC form 10-K, Annual ReportEDGAR Online(Fri, Mar 15)
- Sunshine Biopharma Commences Negotiations With Contract Manufacturing Organizations for Production of Its Multidrug-Resistant Breast Cancer Drug, Adva-27aMarketwired(Thu, Mar 14)
- Sunshine Biopharma Reports on IND Research for Its Novel Breast Cancer Drug Candidate, Adva-27aMarketwired(Tue, Feb 26)
- SUNSHINE BIOPHARMA, INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and EEDGAR Online(Mon, Feb 25)
- Advanomics Corporation, the Parent Company of Sunshine Biopharma, Files a New Patent Application for Its Multidrug Resistance Adva-27a Anticancer CompoundMarketwired(Tue, Jan 15)
- Sunshine Biopharma Completes Another IND-Enabling Study: Adva-27a Is Found to Be Effective Against Multidrug Resistant Uterine Cancer CellsMarketwired(Mon, Dec 10)
- Sunshine Biopharma Completes Six IND-Enabling Studies for Its Anticancer Compound, Adva-27aMarketwired(Tue, Dec 4)
- SUNSHINE BIOPHARMA, INC Files SEC form 8-K, Other EventsEDGAR Online(Thu, Nov 29)
- Advanomics Corporation, the Parent Company of Sunshine Biopharma, Completes Acquisition of Adva-27a PatentsMarketwired(Tue, Nov 27)
Press Releases
- Sunshine Biopharma's Anticancer Drug Candidate, Adva-27a, Is Unaffected by the Recent Supreme Court Ruling on Patentability of Human GenesMarketwired(Wed 8:00AM EDT)
- Sunshine Biopharma Announces That Its Breast Cancer Drug Candidate, Adva-27a, Also Destroys Pancreatic Cancer CellsMarketwired(Tue, Jun 4)
Reports
- No Reports available for SBFM at this time.